TrialJournal of managed care & specialty pharmacy2020

Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets.

Anthony J Cannon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.